top of page

Osteosarcoma and PTHrp

Parathyroid hormone receptor 1
(PTHR1) is a prognostic indicator
in canine osteosarcoma

Al-Khan. 2020.

PTHrp expression in osteosarcoma tumor tissue is associated with a more guarded prognosis.

Image by Conor Sexton

Osteosarcoma metastasis after initial treatment

Prognosis for dogs with stage III osteosarcoma following treatment with amputation and chemotherapy with and without metastasectomy

Turner. 2017.

Dogs receiving surgery to remove metastatic pulmonary nodules who met criteria as good candidates lived longer (8 months) than those who did not (1.5 months) after diagnosis of metastasis. 

Criteria for surgery included:

  • less than 3 pulmonary nodules 

  • Disease free > 9 months after amputation

Image by Wesley Tingey

Stage III OSA

Evaluation of survival time
in dogs with stage III osteosarcoma
that undergo treatment: 90 cases (1985–2004)

Boston. 2006.

Dogs with metastatic osteosarcoma at the time of initial diagnosis lived longest when treated palliatively with radiation and chemotherapy.

surgery: 3 days

NSAIDs alone: 1 month

Surgery and chemotherapy: 3 months

Radiation and chemotherapy: 4 months

Image by Silas Baisch

Hemangiosarcoma and time to first Chemotherapy

Timely adjuvant chemotherapy improves outcome in dogs with non-metastatic splenic hemangiosarcoma undergoing splenectomy

Faroni. 2023

Starting chemotherapy within 3 weeks of splenectomy is important  for survival duration in dogs with stage II or lower splenic hemangiosarcoma.

Image by Renè Müller

Neuroimmune Regulation in Cancer Therapy 

Image by JJ Ying

Angiogenesis

Broad targeting of angiogenesis for cancer prevention and therapy

Wang. 2015.

Inhibition of tumor angiogenesis has become a clinical anti-cancer strategy in line with chemotherapy, radiotherapy and surgery, which underscore the critical importance of the angiogenic switch during early tumor development. 

Red Leaves
bottom of page